Whilst at Lilly’s Erl Wood at 50 celebration event, we sat down with David Reynolds, Chief Scientific Officer at Alzheimer’s Research UK (ARUK). David tells us about the partnership between ARUK and Lilly (UK), and shares his thoughts on the future of Alzheimer’s research.
David Reynolds is the Chief Scientific Officer of ARUK, which is UK’s leading research charity aiming to defeat dementia. Previously David worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and later Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain.
This content has been financially supported by Lilly.